Viewing data from:

LEVOLEUCOVORIN CALCIUM

ANDA

LEVOLEUCOVORIN CALCIUM | A203563 | SANDOZ INC

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Levoleucovorin Calcium (2023)

Total Spending

$27K

Total Claims

Beneficiaries

—

Avg Cost/Unit

$5.39

Spending Trend

$22K(2019)→$82K(2020)→$86K(2021)→$37K(2022)→$27K(2023)

YoY Change:-34.6%

5yr CAGR:-1.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

GMT FINE CHEMICALS SALEVOLEUCOVORIN CALCIUM

DMF 251982011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Mar 11, 2015	ORIG -1	View Letter (PDF)
Mar 11, 2015	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)

0 patents0 exclusivities▴

SOLUTION;INTRAVENOUS | Approved: Mar 9, 2015

No patent or exclusivity listings for this strength.

#002 — EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

0 patents0 exclusivities▾

SOLUTION;INTRAVENOUS | Approved: Mar 9, 2015